A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

1,534

Participants

Timeline

Start Date

March 5, 2020

Primary Completion Date

August 31, 2040

Study Completion Date

August 31, 2046

Conditions

Neuroendocrine Tumors

Interventions

DRUG

[68]Ga-HA-DOTATATE

All participants will be injected with \[68\]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.

Trial Locations (1)

RECRUITING

Cross Cancer Institute, Edmonton

All Listed Sponsors

lead

AHS Cancer Control Alberta

OTHER